BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23797237)

  • 21. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.
    Joosten SC; Deckers IA; Aarts MJ; Hoeben A; van Roermund JG; Smits KM; Melotte V; van Engeland M; Tjan-Heijnen VC
    Epigenomics; 2017 Sep; 9(9):1243-1257. PubMed ID: 28803494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation based biomarkers in colorectal cancer: A systematic review.
    Lam K; Pan K; Linnekamp JF; Medema JP; Kandimalla R
    Biochim Biophys Acta; 2016 Aug; 1866(1):106-20. PubMed ID: 27385266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global DNA hypomethylation in prostate cancer development and progression: a systematic review.
    Zelic R; Fiano V; Grasso C; Zugna D; Pettersson A; Gillio-Tos A; Merletti F; Richiardi L
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):1-12. PubMed ID: 25384337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?
    Zhao Z; Stephan C; Weickmann S; Jung M; Kristiansen G; Jung K
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer.
    Rybicki BA; Rundle A; Kryvenko ON; Mitrache N; Do KC; Jankowski M; Chitale DA; Trudeau S; Belinsky SA; Tang D
    Int J Cancer; 2016 Jun; 138(12):2884-93. PubMed ID: 26860439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
    Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
    Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
    Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global methylation profiling for risk prediction of prostate cancer.
    Mahapatra S; Klee EW; Young CY; Sun Z; Jimenez RE; Klee GG; Tindall DJ; Donkena KV
    Clin Cancer Res; 2012 May; 18(10):2882-95. PubMed ID: 22589488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
    Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
    Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
    Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity.
    Campbell JM; Raymond E; O'Callaghan ME; Vincent AD; Beckmann KR; Roder D; Evans S; McNeil J; Millar J; Zalcberg J; Borg M; Moretti KL
    Clin Genitourin Cancer; 2017 Oct; 15(5):e827-e834. PubMed ID: 28666689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Detection of DNA hypermethylation as a potential biomarker for prostate cancer].
    Tilandyová P; Kajo K; Kliment J; Plank L; Lasabová Z
    Klin Onkol; 2010; 23(5):293-9. PubMed ID: 21061679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The epigenetic promise for prostate cancer diagnosis.
    Van Neste L; Herman JG; Otto G; Bigley JW; Epstein JI; Van Criekinge W
    Prostate; 2012 Aug; 72(11):1248-61. PubMed ID: 22161815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens.
    Epstein JI
    J Urol; 2011 Sep; 186(3):790-7. PubMed ID: 21788055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease.
    Reis IM; Ramachandran K; Speer C; Gordian E; Singal R
    Br J Cancer; 2015 Jul; 113(3):460-8. PubMed ID: 26171936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
    Chade DC; Eastham J; Graefen M; Hu JC; Karnes RJ; Klotz L; Montorsi F; van Poppel H; Scardino PT; Shariat SF
    Eur Urol; 2012 May; 61(5):961-71. PubMed ID: 22280856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.